Fig. 5.

Comparable toxicity prediction ability of hiHeps to PHHs. a Comparison of the TC₅₀ values in hiHeps, PHHs and HepG2 cells with 25 compounds. The light blue region represents a less than 2.5-fold difference of TC₅₀ between compared cell types. n = 3 for all compounds in hiHeps, PHHs and HepG2 cells, except that n = 2 for AFB1 in PHHs. The correlation between groups was evaluated by the Pearson correlation coefficient (r). b Time- and dose-dependent chronic toxicity of troglitazone in hiHeps. Mitochondrial activities were normalized to DMSO-treated cultures at corresponding day. n = 6. c Fluorescence evaluation of the pathological effects of DILI in hiHeps. Steatosis (up) and phospholipidosis (down) were evaluated in hiHeps after exposure to steatosis-causing compounds and phospholipidosis-causing compounds, respectively. Rifampin (non-steatosis/phospholipidosis-causing drug) or DMSO treatment were set as controls. For all compounds, images were captured at the concentration of 80% TC₅₀. For all measurements, ‘n’ represents the number of biological replicates. The scale bars represent 50 μm. Data are presented as mean ± SEM